Top news


Position : Home Page >> News
Dorzagliatin Tablet Approved for Marketing
    Pubtime: 2022-10-10

  Recently, the Dorzagliatin Tablet (Chinese trade name: 华堂宁) as a NME (new molecule entity) is approved for marketing by China NMPA. Dorzagliatin, developed by HUA Medicine Shanghai, is approved for improving the blood glucose control for adult patients with type 2 diabetes.

  Dozaglietine is a glucokinase (GK) activator, which can act on GK target in organs of pancreas, intestine and liver to regulate glucose storage and output, so as to restore the blood glucose homeostasis in patients with type 2 diabetes. This drug provides a new treatment option available for patients with type 2 diabetes.

Produced By CMS 网站群内容管理系统 publishdate:2022/10/12 08:31:13